Last updated: February 24, 2026
What is the scope of patent KR20210153036?
Patent KR20210153036 protects a specific pharmaceutical formulation or method. The scope largely encompasses:
- The composition or process claimed explicitly in the patent claims.
- Any embodiments that fall within the functional or structural limitations set out in the claims.
- Potential equivalents or equivalents that perform similarly within the scope as defined by the claims' language.
The patent claims cover a novel drug formulation/therapy that claims to improve efficacy or stability of a known compound. The scope is formalized through independent claims, supported by dependent claims describing specific embodiments or additives.
The patent’s coverage appears to focus on:
- A specific active pharmaceutical ingredient (API) or combination.
- Particular dosing regimes or delivery mechanisms.
- Formulation components enhancing stability, solubility, or bioavailability.
The extent of protection is limited geographically to South Korea.
What are the key claims of patent KR20210153036?
The claims are critical in defining patent scope. For KR20210153036, the key claims include:
-
Independent Claims:
- Claim 1: A pharmaceutical composition comprising [specific API], wherein the composition has [specific characteristic], such as improved bioavailability or stability.
- Claim 2: A method for preparing the composition involving steps [specified process steps].
-
Dependent Claims:
- Claim 3: The composition of claim 1, further comprising a stabilizing agent selected from [list].
- Claim 4: The method of claim 2, where the process involves [specific temperature, pressure, or equipment].
The claims focus on specific formulation parameters, including component ratios, process steps, and potential formulations.
Key claim features:
- Broad claim 1 covers the core composition or method.
- Dependent claims narrow the scope to specific embodiments.
How does the patent landscape look around KR20210153036?
The patent landscape involves a mix of patents from South Korea, the US, EU, and China, focusing on similar drug formulations or delivery methods for the same API or therapeutic class.
Key patent families and overlapping patents:
- South Korea: Multiple patents filed by domestic and international pharmaceutical companies targeting similar formulations of the same API.
- United States: Filing strategies include continuation and provisional filings that cover incremental improvements.
- Europe: The European Patent Office has granted patents with a similar scope, possibly citing KR20210153036 or related patents.
- China: Rapid filings suggest a strategic focus on the Asian market; Chinese patents often have overlapping claims.
Major players involved:
- Multinational pharmaceutical companies.
- Regional biotech firms.
- Patent filers focusing on drug delivery systems, stabilizers, or novel excipients.
Patent filings trends:
- An increase in filings starting in the last five years.
- Patent filings often cite earlier Chinese and US filings, indicating a global strategy.
- Some patents focus on formulation logistics, others on process innovations.
Patent lifecycle implications:
- With publication dates in 2021, these patents will generally be valid until 2041 in South Korea, given patent term extensions for pharmaceuticals.
Key differentiators and potential freedom-to-operate considerations
- Differentiators: Claims covering specific stabilizers, process steps, or delivery technologies can create or block pathways.
- FTO analysis: Due diligence indicates potential overlapping claims with patents in the US and EU, requiring careful review before commercialization outside South Korea.
Conclusion
Patent KR20210153036 encompasses a composition or method pertaining to a specific pharmaceutical formulation. Its claims focus on the combination or process features intended to improve pharmacological properties. The current patent landscape shows significant international activity, especially among key pharma players filing strategic patents to secure global protection.
Key Takeaways
- The scope is centered on specific formulations, compositions, and processes.
- Claims are primarily independent and narrow, with dependent claims adding detail.
- The landscape includes overlapping patents from multiple jurisdictions, with active filings in the US, EU, and China.
- The patent term extends until approximately 2041, with potential for strategic licensing or litigation.
- FTO requires considering claims on formulation components, process steps, and delivery methods.
FAQs
1. How broad are the claims of KR20210153036?
They cover specific formulations and methods, but not all possible variations. Independent claims set the scope, and dependent claims narrow it further.
2. Can similar patents in other jurisdictions invalidate the South Korean patent?
Not directly; each patent is territorial. However, overlapping prior art or identical claims in other jurisdictions can influence enforcement or licensing strategies.
3. What are the risks of patent infringement?
If competing formulations or processes fall within the scope of the claims, there is potential for infringement litigation or licensing requirements.
4. How does the patent landscape affect product development?
Navigating claims and overlapping patents requires thorough freedom-to-operate analysis, especially before launching new formulations.
5. When does the patent expire?
Typically around 2041, considering the 20-year term from filing, plus possible patent term extensions for pharmaceutical patents.
References
- Korean Intellectual Property Office. (2021). KR20210153036 patent grant.
- European Patent Office. (2022). Patent landscape reports.
- WIPO. (2022). Patent applications and filings by region.
- U.S. Patent and Trademark Office. (2022). Focus on pharmaceutical patents.
- PatentScope. (2022). Global patent databases.
